SPONSORED CONTENT

Large study shows that a simple blood test can accurately differentiate between Benign and Malignant Lesions

November 09, 2020 23:30 IST
Tennis player James Blake
Datar Cancer Genetics

London [UK], November 9 (ANI/PRNewswire): A large, landmark study published in the American Cancer Society's prestigious journal 'Cancer Cytopathology' shows that a simple non-invasive blood test (liquid biopsy) can accurately differentiate between non-cancerous tumors versus cancerous growths.

These findings were based on a multi-institutional, international collaborative study sponsored by Datar Cancer Genetics where the investigators evaluated blood samples from more than 30,000 participants, which included ~9,000 known cases and ~6,000 suspected cases of cancers, 700 individuals with non-cancerous tumors and 14,000 healthy individuals. The study encompassed 27 types of solid organ cancers including brain tumors.

The investigators evaluated the presence of circulating, tiny clusters of tumors, highly prevalent in the blood of cancer patients and undetectable in individuals without cancer. The investigators could also establish precise organ affected by the tumor with more than 90 per cent accuracy.

Significantly, the test will greatly help individuals reporting with suspicious growths in various organs such as breast, lung, prostate, colon, brain. It is noteworthy that a large proportion of individuals who undergo biopsy on suspicion of malignancy are detected with benign tumors who could be spared risky invasive and resource intensive biopsies. Also, the blood test can help in the diagnosis of cases where invasive biopsies are unviable due to various reasons such as location of the tumor close to a vital organ or blood vessel or reluctance of patients besides co-morbidities.

The technology and the test are developed by Datar Cancer Genetics. The test is expected to be commercially available shortly. These findings are bound to have a profound impact on cancer diagnosis.

Commenting upon the results, Nicholas Plowman, MD, Medical Oncologist at Department of Clinical Oncology, St Bartholomew's Hospital, London, United Kingdom, and one of the authors of the paper said that 'This study is the largest of its kind and shows the meaningful potential of liquid biopsies, which so far have been grossly under-rated, at least partly as the previous capture methods were inferior. Harvesting tumor clusters from peripheral blood is akin to a non-invasive micro-biopsy of the tumor. Evaluation of these clusters can facilitate diagnostic triaging as well as guidance in suspected cancer cases. The test is not only patient friendly, but it can also significantly reduce the burden on the already overburdened cancer diagnosis infrastructure.'

The research is published online (https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22366).

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

 

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Large study shows that a simple blood test can accurately differentiate between Benign and Malignant Lesions

London [UK], November 9 (ANI/PRNewswire): A large, landmark study published in the American Cancer Society's prestigious journal 'Cancer Cytopathology' shows that a simple non-invasive blood test (liquid biopsy) can accurately differentiate between non-cancerous tumors versus cancerous growths.

These findings were based on a multi-institutional, international collaborative study sponsored by Datar Cancer Genetics where the investigators evaluated blood samples from more than 30,000 participants, which included ~9,000 known cases and ~6,000 suspected cases of cancers, 700 individuals with non-cancerous tumors and 14,000 healthy individuals. The study encompassed 27 types of solid organ cancers including brain tumors.

The investigators evaluated the presence of circulating, tiny clusters of tumors, highly prevalent in the blood of cancer patients and undetectable in individuals without cancer. The investigators could also establish precise organ affected by the tumor with more than 90 per cent accuracy.

Significantly, the test will greatly help individuals reporting with suspicious growths in various organs such as breast, lung, prostate, colon, brain. It is noteworthy that a large proportion of individuals who undergo biopsy on suspicion of malignancy are detected with benign tumors who could be spared risky invasive and resource intensive biopsies. Also, the blood test can help in the diagnosis of cases where invasive biopsies are unviable due to various reasons such as location of the tumor close to a vital organ or blood vessel or reluctance of patients besides co-morbidities.

The technology and the test are developed by Datar Cancer Genetics. The test is expected to be commercially available shortly. These findings are bound to have a profound impact on cancer diagnosis.

Commenting upon the results, Nicholas Plowman, MD, Medical Oncologist at Department of Clinical Oncology, St Bartholomew's Hospital, London, United Kingdom, and one of the authors of the paper said that 'This study is the largest of its kind and shows the meaningful potential of liquid biopsies, which so far have been grossly under-rated, at least partly as the previous capture methods were inferior. Harvesting tumor clusters from peripheral blood is akin to a non-invasive micro-biopsy of the tumor. Evaluation of these clusters can facilitate diagnostic triaging as well as guidance in suspected cancer cases. The test is not only patient friendly, but it can also significantly reduce the burden on the already overburdened cancer diagnosis infrastructure.'

The research is published online (https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22366).

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22